Shares of biopharmaceutical developer 3SBio Inc. dropped 5.4% to HK$29.98 on Tuesday, hitting their lowest level since November 24 and marking their biggest one-day percentage decline since November 21. The stock was the top percentage loser in the Hang Seng Composite Health Care Index, which fell 1%.

Catalyst:
The decline followed the company's announcement of a plan to raise HK$3.12 billion (approximately $400.49 million) through the placement of 105.17 million new shares to third-party investors.

Placement Details:

• The new shares will be issued at HK$29.62 per share, representing a 6.5% discount to Monday’s closing price of HK$31.68.
• Proceeds will be used to advance clinical research in China and the United States on innovative drug candidates in the R&D stage, accelerating pipeline progress, among other corporate purposes.

Year-to-Date Performance:
Despite the recent pullback, 3SBio's stock has surged 397% year-to-date, significantly outperforming the Hang Seng Biotech Index, which is up 80.1%.

(Exchange rate: $1 = HK$7.7904)